Jump to main content
Jump to site search


A simple, sensitive, high-resolution, customized, reverse phase ultra-high performance liquid chromatographic method for related substances of therapeutic peptide (Bivalirudin Trifluoroacetate) using Quality by Design approach

Abstract

Among all chemical sameness characterization tests of Therapeutic Peptides (TPs), one of the most significant and challenging aspects is to demonstrate comparable impurity profiles (both qualitative & quantitative) between the generic product and reference listed drug (RLD). Though multiple state of the art orthogonal analytical methods are being used for the identification and quantification of the related impurities in TPs, it is important that the developed methods are simple, selective, sensitive, and can be easily implementable in the quality control laboratories. The current published chromatographic (HPLC or UHPLC) methods for the quantification of related substances in TPs rarely use non-mass spectrometry compatible ion pairing reagents (NMS-IPRs) in the mobile phase composition over the mass spectrometry compatible ion pairing reagents (MS-IPRs), due to their compatibility issues with the high-resolution mass-based detection methods. We hypothesize that achieving mixed mode stationary phase characteristics using hydrophobic NMS-IPRs such as sodium 1-butanesulfonate, at concentrations < 10 mM in the diethanolammonium phosphate buffer (pH 2.9) on C-18 stationary phase, would be able to resolve critical impurities such as Penta-Gly, D-Asn, and Tri-Gly using single UHPLC method, and is also selective to all other related impurities of Bivalirudin (BIV) cited in the literature. Furthermore, customization of column dimensions (300 mm  2.1 mm  1.8 m) helped in achieving a resolution (Rs) > 2.0 between the Penta-Gly & BIV, and a peak to valley ratio (Hp/Hv) > 4.0 between BIV & D-Asn and D-Asn & Tri-Gly impurities. The developed method is sensitive (LOQ ~ 0.05% with respect to analyte concentration), precise, accurate, and linear in the range of 1 g/mL to 2500 g/mL. This method is rugged, robust, and easily implementable in the quality control laboratories for monitoring the related impurities of Bivalirudin.

Back to tab navigation

Publication details

The article was received on 16 Sep 2019, accepted on 22 Nov 2019 and first published on 22 Nov 2019


Article type: Paper
DOI: 10.1039/C9AY01998G
Anal. Methods, 2019, Accepted Manuscript

  •   Request permissions

    A simple, sensitive, high-resolution, customized, reverse phase ultra-high performance liquid chromatographic method for related substances of therapeutic peptide (Bivalirudin Trifluoroacetate) using Quality by Design approach

    Y. Komaravolu, V. Dama, S. Ch and M. T. Chary, Anal. Methods, 2019, Accepted Manuscript , DOI: 10.1039/C9AY01998G

Search articles by author

Spotlight

Advertisements